Plain-English translation of NCT06673017 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which is a small implant designed to deliver medication directly to your pancreas during surgery. You would receive this implant along with standard chemotherapy drugs that are already used to treat pancreatic cancer. Doctors want to find the safest and most effective dose of this medication when combined with chemotherapy before surgery to remove the tumor.
Pancreatic cancer is very aggressive, and current treatments don't work well enough for many patients. This trial exists to see whether delivering medication directly to the tumor site through an implant, combined with chemotherapy, might help more patients survive longer and have better outcomes after surgery.
You likely qualify if…
You likely don't qualify if…
If you join, you would first have a laparoscopy (a minimally invasive surgical procedure to look inside your abdomen and confirm your cancer). Then the implant would be placed during this procedure, and you would receive standard chemotherapy infusions alongside it. You would be followed closely for at least 24 months with regular visits to check how you are responding to treatment and monitor for any side effects, including scans and blood tests.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States